Clinical trial
Title XELOX FOR SALIVARY GLAND CANCERS
NCT00101075 · Dana-Farber Cancer Institute, Other · Terminated
Key facts
| NCT number | NCT00101075 |
|---|---|
| Title | Title XELOX FOR SALIVARY GLAND CANCERS |
| Official title | Phase II Study of Capecitabine and Oxaliplatin (XELOX) in Patients With Locally Advanced, Incurable, Salivary Gland Cancers |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH Sanofi-Synthelabo Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug |
| Interventions | Capecitabine, Oxaliplatin |
| Enrollment | 9 |
| Start date | Oct 1, 2004 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2008 |
| First posted | Jan 10, 2005 |
| Last update posted | Feb 27, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: